Vicarious Surgical (RBOT) Net Income towards Common Stockholders (2020 - 2025)
Vicarious Surgical's (RBOT) quarterly Net Income towards Common Stockholders came in at -$11.1 million in Q3 2025, up 35.3% year-over-year from -$8.2 million in Q3 2024, and up 16.32% quarter-over-quarter from -$13.2 million in Q2 2025.
Analysis
Vicarious Surgical (RBOT) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Vicarious Surgical (RBOT) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$11.1 million the latest figure, recorded in Q3 2025.
- On a quarterly basis, Net Income towards Common Stockholders rose 35.3% year-over-year to -$11.1 million in Q3 2025; TTM through Sep 2025 was -$53.6 million, a 14.12% increase from a year earlier, with the FY2024 full-year figure at -$63.2 million, up 11.04% from the prior year.
- Net Income towards Common Stockholders was -$11.1 million for Q3 2025 at Vicarious Surgical, up from -$13.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $42.5 million in Q1 2022 and troughed at -$45.1 million in Q3 2021.
- A 5-year average of -$10.7 million and a median of -$13.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders sank 24757.7% in 2021 and soared 912.98% in 2022, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at $21.8 million in 2021, then slumped by 151.32% to -$11.2 million in 2022, then retreated by 17.27% to -$13.1 million in 2023, then decreased by 6.22% to -$13.9 million in 2024, then grew by 20.59% to -$11.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$11.1 million (Q3 2025), -$13.2 million (Q2 2025), and -$15.4 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Vicarious Surgical | 231,626.35 | -14.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -11.06 Mn |
| Jun 30, 2025 | -13.22 Mn |
| Mar 31, 2025 | -15.39 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Sep 30, 2024 | -17.09 Mn |
| Jun 30, 2024 | -15.21 Mn |
| Mar 31, 2024 | -17.00 Mn |
| Dec 31, 2023 | -13.11 Mn |
| Sep 30, 2023 | -15.70 Mn |
| Jun 30, 2023 | -15.33 Mn |
| Mar 31, 2023 | -26.92 Mn |
| Dec 31, 2022 | -11.18 Mn |
| Sep 30, 2022 | -24.74 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | 42.53 Mn |
| Dec 31, 2021 | 21.79 Mn |
| Sep 30, 2021 | -45.12 Mn |
| Jun 30, 2021 | -6.64 Mn |
| Mar 31, 2021 | -5.23 Mn |
| Dec 31, 2020 | -3.78 Mn |